Disease Modification in Psoriasis Through Early IL-17 Inhibitor Intervention: A Retrospective Cohort Study [0.03%]
通过早期IL-17抑制剂干预修改银屑病的疾病进程：回顾性队列研究
Junchen Chen,Guo Zhou,Yang Sha et al.
Junchen Chen et al.
Methods: We conducted a multicenter retrospective cohort study on moderate-to-severe plaque psoriasis patients who received at least 4 weeks of treatment with Secukinumab or Ixekizumab between April 2019 and April 2023, taking the relapse rate one year after cessation of treatment...Of 141 patients who discontinued treatment after achieving PASI90 for over a year, 24 (88.89%) in the ultra-short disease duration(USDD, psoriasis duration ≤ 1 year) group and 33 (82.5%) in the short disease duration(SDD, psoriasis duration ≤ 2 year) group achieved one year of drug-free remission.
p67phox/NOX2 inhibits psoriasis by regulating the HIF-1α-glycolysis axis via p53-AMPK in keratinocytes [0.03%]
NADPH氧化酶抑制角质细胞HIF-1α-糖酵解轴防治银屑病的研究
Ang Li,Zhou Zhuang,Qingyue Xia et al.
Ang Li et al.
In an imiquimod-induced murine psoriasis model, pharmacologic inhibition of NOX2 by GSK2795039 aggravated psoriasiform inflammation, whereas BML-111, a lipoxin A4 analog, alleviated pathology by restoring p67phox/NOX2 activity and metabolic balance.
Apigenin suppresses keratinocyte hyperproliferation and inflammation in psoriasis by inhibiting CDK2/E2F2 pathway [0.03%]
阿皮辛通过抑制CDK2/E2F2通路抑制银屑病中的角质细胞过度增殖和炎症反应
Abudureyimu Alimujiang,Yutong Kang,Wenjing Wei et al.
Abudureyimu Alimujiang et al.
Methods: Mice with imiquimod (IMQ)-induced psoriasis were treated with QXW or DJC, and the therapeutic effects were evaluated using the Psoriasis Area and Severity Index (PASI), histological analysis, immunohistochemistry, immunofluorescence, RT-PCR, and ELISA....DJC alleviated psoriasis by inhibiting keratinocyte hyperproliferation and the inflammatory response. UPLC-QTOF/MS analysis and LPS-induced HaCaT cell studies identified Apigenin as the principal active compound of DJC.
Prevalence and impact of comorbidities in amyotrophic lateral sclerosis [0.03%]
伴发疾病在肌萎缩侧索硬化患者中的患病率及其影响
Kurt A Jellinger
Kurt A Jellinger
Other comorbidities include sleep disorders, traumatic encephalopathy, sarcoidosis, prionopathies, schizophrenia, cervical spondylotic myelopathy, psoriasis and others.
Hypoxia Exposure Promotes Th17 Cell Differentiation Through Activin A-PKM2 Axis to Exacerbate Autoimmune and Autoinflammatory Diseases [0.03%]
缺氧通过活化素A-PKM2轴促进Th17细胞分化以加重自身免疫和自身炎症性疾病
Yuhui Li,Mengting He,Jie Xu et al.
Yuhui Li et al.
Using an environmental simulation chamber, we subjected mouse models of experimental autoimmune encephalomyelitis (EAE) and psoriasis to hypobaric hypoxia, simulating conditions at an altitude of 6000 m.
Eco-conscious TLC assay for dual psoriasis drugs in plasma: a green analytical approach [0.03%]
用于血浆中银屑病双药的生态意识TLC测定法：一种绿色分析方法
Maimana A Magdy,Basma H Anwar,Nehal F Farid et al.
Maimana A Magdy et al.
Psoriasis is one of the dermatological autoimmune diseases that involve cracking, redness, bleeding and inflammation on the surface of the skin. Sulfasalazine (SUL) is an immunity suppressing and anti-phlogistic drug. Pentoxifylline (PTN) i...
Glucagon-like Peptide-1 Receptor Agonist Use in Patients with Psoriasis is Associated with Lower Incidence of Atherosclerotic Cardiovascular Disease: A Retrospective Cohort Study Using TriNetX [0.03%]
胰高血糖素样肽-1受体激动剂用于银屑病患者与动脉粥样硬化性心血管疾病的较低发病风险相关：一项TriNetX回顾队列研究
Tarun Sontam,Helen Chen,Justin Raman et al.
Tarun Sontam et al.
Discovery of novel PDE4 degraders with in vivo anti-inflammatory efficacy [0.03%]
具有体内抗炎作用的新型PDE4降解剂的发现
Yuanhui Liu,Hongliang Yao,Yanghui Ou et al.
Yuanhui Liu et al.
Phosphodiesterase 4 (PDE4) has been identified to be an effective target for treatment of autoimmune and inflammatory diseases like chronic obstructive pulmonary disease (COPD), psoriasis and asthma.
Psoriasis unveiled: The cellular ballet, molecular symphony, and genetic puzzle [0.03%]
皮炎揭秘——细胞集体舞、分子交响乐和基因难题
Ankita Sharma,Sonia Dhiman,Thakur Gurjeet Singh et al.
Ankita Sharma et al.
This review discusses conventional and innovative gene therapies, which have been found to hit specific cellular and molecular targets to combat psoriasis therapy.
Comparison of hematological inflammatory markers and comorbid conditions in patients with psoriasis vulgaris and lichen planus [0.03%]
寻常型银屑病与扁平苔藓患者的血液炎症标志物及合并症的比较研究
Mehmet Semih Çelik,Hamza Aktaş
Mehmet Semih Çelik
Background and objective: Psoriasis vulgaris (PV) and lichen planus (LP) are inflammatory skin diseases. Systemic inflammatory markers, which may indicate inflammation in these diseases, have been investigated in various ...
耗时 0.09726 秒，为您在
48223910
条记录里面共找到 10000 篇文章 [XML]